JP3738281B2 - 新規な骨芽細胞増殖因子 - Google Patents
新規な骨芽細胞増殖因子 Download PDFInfo
- Publication number
- JP3738281B2 JP3738281B2 JP20125794A JP20125794A JP3738281B2 JP 3738281 B2 JP3738281 B2 JP 3738281B2 JP 20125794 A JP20125794 A JP 20125794A JP 20125794 A JP20125794 A JP 20125794A JP 3738281 B2 JP3738281 B2 JP 3738281B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- bone
- mc3t3
- growth factor
- vol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000963 osteoblast Anatomy 0.000 title description 9
- 239000003102 growth factor Substances 0.000 title description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract 3
- 102100029268 Neurotrophin-3 Human genes 0.000 claims description 30
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000003449 preventive effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 abstract description 30
- 238000000034 method Methods 0.000 abstract description 6
- 102000057714 human NTF3 Human genes 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 2
- 102000004230 Neurotrophin 3 Human genes 0.000 abstract 2
- 230000002503 metabolic effect Effects 0.000 abstract 2
- 229940032018 neurotrophin 3 Drugs 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 40
- 102000047459 trkC Receptor Human genes 0.000 description 12
- 108010064892 trkC Receptor Proteins 0.000 description 12
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 9
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- 239000011575 calcium Substances 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 230000003185 calcium uptake Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000004097 bone metabolism Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 101150025395 trkA gene Proteins 0.000 description 3
- 101150113435 trkA1 gene Proteins 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20125794A JP3738281B2 (ja) | 1994-07-22 | 1994-07-22 | 新規な骨芽細胞増殖因子 |
AT95111224T ATE206930T1 (de) | 1994-07-22 | 1995-07-18 | Verwendung von osteoblast-proliferationsfaktor |
ES95111224T ES2161809T3 (es) | 1994-07-22 | 1995-07-18 | Uso de factor proliferativo osteoblastico. |
DK95111224T DK0704219T3 (da) | 1994-07-22 | 1995-07-18 | Anvendelse af faktor for osteoblastisk celledeling |
EP95111224A EP0704219B1 (en) | 1994-07-22 | 1995-07-18 | Use of osteoblastic proliferative factor |
DE69523250T DE69523250T2 (de) | 1994-07-22 | 1995-07-18 | Verwendung von Osteoblast-Proliferationsfaktor |
PT95111224T PT704219E (pt) | 1994-07-22 | 1995-07-18 | Utilizacao de um factor proliferativo osteoblastico |
AU27105/95A AU693567B2 (en) | 1994-07-22 | 1995-07-20 | A novel osteoblastic proliferative factor |
FI953514A FI953514A (fi) | 1994-07-22 | 1995-07-20 | Uusi osteoblastien proliferaatiotekijä |
KR1019950021475A KR100361717B1 (ko) | 1994-07-22 | 1995-07-21 | 조골세포증식인자 |
US08/505,539 US6080720A (en) | 1994-07-22 | 1995-07-21 | Treatment method of bone and osteoblasts with neurotrophin-3 (NT-3) |
HU9502202A HU217082B (hu) | 1994-07-22 | 1995-07-21 | Humán neurotrofin-3 alkalmazása anyagcserével kapcsolatos csontbetegségek kezelésére alkalmas gyógyászati készítmények előállítására |
CA002154403A CA2154403A1 (en) | 1994-07-22 | 1995-07-21 | A novel osteoblast proliferative factor |
NO952912A NO952912L (no) | 1994-07-22 | 1995-07-21 | En ny osteoblastisk proliferativ faktor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20125794A JP3738281B2 (ja) | 1994-07-22 | 1994-07-22 | 新規な骨芽細胞増殖因子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0834744A JPH0834744A (ja) | 1996-02-06 |
JP3738281B2 true JP3738281B2 (ja) | 2006-01-25 |
Family
ID=16437950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP20125794A Expired - Fee Related JP3738281B2 (ja) | 1994-07-22 | 1994-07-22 | 新規な骨芽細胞増殖因子 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6080720A (ko) |
EP (1) | EP0704219B1 (ko) |
JP (1) | JP3738281B2 (ko) |
KR (1) | KR100361717B1 (ko) |
AT (1) | ATE206930T1 (ko) |
AU (1) | AU693567B2 (ko) |
CA (1) | CA2154403A1 (ko) |
DE (1) | DE69523250T2 (ko) |
DK (1) | DK0704219T3 (ko) |
ES (1) | ES2161809T3 (ko) |
FI (1) | FI953514A (ko) |
HU (1) | HU217082B (ko) |
NO (1) | NO952912L (ko) |
PT (1) | PT704219E (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5878477B2 (ja) * | 2010-01-15 | 2016-03-08 | ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー | 骨の治癒を加速するためのバナジウム化合物の使用 |
WO2012079024A2 (en) | 2010-12-10 | 2012-06-14 | University Of Medicine And Dentistry Of New Jersey | Implantable devices coated with insulin-mimetic agent composites and methods thereof |
US20140322292A1 (en) | 2010-12-10 | 2014-10-30 | Rutgers, The State University Of New Jersey | Insulin-mimetics as therapeutic adjuncts for bone regeneration |
US9931348B2 (en) | 2011-07-06 | 2018-04-03 | Rutgers, The State University Of New Jersey | Vanadium compounds as therapeutic adjuncts for cartilage injury and repair |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR1000980B (el) * | 1989-08-30 | 1993-03-31 | Max Planck Gesellschaft | Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο. |
WO1995030434A1 (en) * | 1994-05-06 | 1995-11-16 | Regeneron Pharmaceuticals, Inc. | Methods based on the role of neurotrophin 3 in female reproduction |
-
1994
- 1994-07-22 JP JP20125794A patent/JP3738281B2/ja not_active Expired - Fee Related
-
1995
- 1995-07-18 DK DK95111224T patent/DK0704219T3/da active
- 1995-07-18 DE DE69523250T patent/DE69523250T2/de not_active Expired - Fee Related
- 1995-07-18 AT AT95111224T patent/ATE206930T1/de not_active IP Right Cessation
- 1995-07-18 EP EP95111224A patent/EP0704219B1/en not_active Expired - Lifetime
- 1995-07-18 ES ES95111224T patent/ES2161809T3/es not_active Expired - Lifetime
- 1995-07-18 PT PT95111224T patent/PT704219E/pt unknown
- 1995-07-20 AU AU27105/95A patent/AU693567B2/en not_active Ceased
- 1995-07-20 FI FI953514A patent/FI953514A/fi not_active IP Right Cessation
- 1995-07-21 US US08/505,539 patent/US6080720A/en not_active Expired - Fee Related
- 1995-07-21 KR KR1019950021475A patent/KR100361717B1/ko not_active IP Right Cessation
- 1995-07-21 NO NO952912A patent/NO952912L/no not_active Application Discontinuation
- 1995-07-21 HU HU9502202A patent/HU217082B/hu not_active IP Right Cessation
- 1995-07-21 CA CA002154403A patent/CA2154403A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR100361717B1 (ko) | 2003-07-07 |
JPH0834744A (ja) | 1996-02-06 |
EP0704219A2 (en) | 1996-04-03 |
AU693567B2 (en) | 1998-07-02 |
DK0704219T3 (da) | 2002-02-04 |
ES2161809T3 (es) | 2001-12-16 |
ATE206930T1 (de) | 2001-11-15 |
EP0704219A3 (en) | 1997-12-10 |
US6080720A (en) | 2000-06-27 |
CA2154403A1 (en) | 1996-01-23 |
FI953514A (fi) | 1996-01-23 |
DE69523250D1 (de) | 2001-11-22 |
HU217082B (hu) | 1999-11-29 |
NO952912L (no) | 1996-01-23 |
HUT73185A (en) | 1996-06-28 |
PT704219E (pt) | 2002-03-28 |
HU9502202D0 (en) | 1995-09-28 |
NO952912D0 (no) | 1995-07-21 |
KR960003741A (ko) | 1996-02-23 |
DE69523250T2 (de) | 2002-07-04 |
FI953514A0 (fi) | 1995-07-20 |
EP0704219B1 (en) | 2001-10-17 |
AU2710595A (en) | 1996-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yano et al. | Neurotrophin receptor structure and interactions | |
US9605073B2 (en) | Modulation of activity of neurotrophins | |
Zhang et al. | Hepatocyte growth factor protects cultured rat cerebellar granule neurons from apoptosis via the phosphatidylinositol‐3 kinase/Akt pathway | |
EP1156820B1 (en) | Use of vascular endothelial growth factor-2 (vegf-2) | |
Zihlmann et al. | The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons | |
US8101571B2 (en) | Treatment methods using NGF variants | |
US7223724B1 (en) | Use of vascular endothelial growth factor to treat photoreceptor cells | |
US20020032153A1 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
JP3738281B2 (ja) | 新規な骨芽細胞増殖因子 | |
US6696410B1 (en) | Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors | |
CN110869386A (zh) | 重组神经生长因子的组合物和方法 | |
US7132397B1 (en) | Bone morphogenetic protein antagonist based on the mature protein | |
US6630142B2 (en) | Method of treating fibroproliferative disorders | |
JP4094814B2 (ja) | 血管新生抑制剤 | |
JPH09188630A (ja) | 膵臓機能改善剤 | |
US6569419B2 (en) | Methods for promoting production of myelin by Schwann cells | |
Wimalawansa et al. | Rapid publication: Hypocalcemic actions of amylin amide in humans | |
AU773990B2 (en) | Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors | |
US20230000955A1 (en) | Thrombomodulin functional domains for use in promoting osteoblast functions and bone healing | |
Bürvenich et al. | Calcitonin gene-related peptide promotes differentiation, but not survival, of rat mesencephalic dopaminergic neurons in vitro | |
AU718998B2 (en) | Variants of ciliary neurotrophic factor with enhanced receptor selectivity and method for their selection | |
WO1995015176A1 (en) | Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5 | |
US6723696B1 (en) | Bone resorption inhibitors | |
WO1995033058A1 (fr) | Codage genique pour le recepteur modifie de la proteine morphogenetique osseuse | |
JP2003052387A (ja) | 線維芽細胞増殖因子13 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050809 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050909 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |